The Journal
Long-form research on GLP-1 pricing, regulation and program structure — every piece grounded in the same capture-dated database as the rest of the site. The content roadmap runs 250 pieces deep; these are live now.
Cheapest Compounded Tirzepatide Online in 2026: Real Prices, Real Rules, Real Trade-offs
Compounded tirzepatide prices in 2026, written out in words: the $169 promotional floor, the $258 no-promo benchmark, the $249–$549 compliant-market range, the $449 FDA-approved alternative, the law after the shortage ended, and the seven checks that matter more than the price.
Updated 2026-08-11
NexLife Tirzepatide Review 2026: Promotional Pricing, Verified — Is It Actually Cheap?
NexLife's compounded tirzepatide promotional price is $169 a month billed monthly and $139 a month on the 12-month plan through August 31, 2026 — the lowest month-to-month figure we track. Full audit: is it legitimate, what the Flat Forever lock-in means, how it compares to Trimi, bmiMD and Henry Meds, and what to verify before enrolling.
Updated 2026-08-11
Cheapest Compounded Tirzepatide With No Annual Commitment (2026): Month-to-Month Options Ranked
Not willing to pay a year upfront? The cheapest verified all-in compounded tirzepatide programs with no annual lock-in, ranked by month-to-month cost in 2026: NexLife $169, Henry Meds $179, bmiMD $179, and why the $125 programs require exactly what you're trying to avoid.
Updated 2026-08-11
Cheapest Compounded Semaglutide Online in 2026: Every Real Price, In Words
The cheapest compounded semaglutide in August 2026 is $129 a month month-to-month (bmiMD) and $99 a month on twelve-month plans (bmiMD, HealthRX, Trimi). Every rankable program narrated in prose, the $349 Wegovy and $149 oral Wegovy benchmarks, the annual arithmetic, and the checks that outrank the price.
Updated 2026-08-11
Compounded Tirzepatide vs Zepbound in 2026: The Real Cost Comparison
Zepbound vials cost $299–$449 a month through LillyDirect with a 45-day refill rule; compounded tirzepatide runs $125–$179 at the credible low end. The full arithmetic: what the $1,800–$3,900 annual spread buys, when each path wins, the insurance and Medicare routes that beat both, and the one calendar rule that can double a brand month.
Updated 2026-08-11
Is Compounded Tirzepatide Legal in 2026? The Complete Status, Dated
Yes — through one narrow lane: patient-specific 503A prescriptions under documented clinical need. The full dated timeline: shortage resolved December 19, 2024, grace periods ended spring 2025, 503B bulk compounding over March 19 2025, FDA's April 2026 proposal, 730+ adverse-event reports, Lilly's litigation, and exactly what stays legal for the patient.
Updated 2026-08-11
Tirzepatide vs Semaglutide in 2026: The Head-to-Head Trial, Every Price, One Framework
In the only head-to-head trial (SURMOUNT-5), tirzepatide beat semaglutide 20.2% to 13.7% average weight loss at 72 weeks. Semaglutide costs $40–$270 less a month at every tier. The mechanism, the trial read honestly, the full price ladders, cost per percentage point, and how a clinician actually chooses.
Updated 2026-08-11
Semaglutide Units to Mg: Why There Is No Universal Dosage Chart (And the One Calculation That Matters)
Searches for a compounded semaglutide dosage chart are up 200% — and every universal chart is wrong, because syringe units measure volume while your dose is in milligrams, and the conversion depends entirely on your vial's concentration. The actual math, the standard titration schedule from the FDA label, and the questions that keep you safe.
Updated 2026-08-11
Zepbound Vial Prices by Dose in 2026: The $299–$449 Ladder and the 45-Day Rule That Governs It
Every Zepbound self-pay price by dose — $299 at 2.5 mg, $399 at 5 mg, $449 from 7.5 to 15 mg — plus the 45-day refill rule, the $599–$1,049 off-window penalty, vials versus KwikPen, and the annual math at each dose.
Updated 2026-08-11
Best GLP-1 Program With Insurance in 2026: The $25 Copay Path, Step by Step
With commercial coverage, brand Zepbound or Wegovy at a $25 copay beats every cash program in existence. How coverage actually gets used: the benefits check, the prior authorization, the appeal, Ro's concierge, the manufacturer savings cards, and Medicare's $50 GLP-1 bridge.
Updated 2026-08-11
Retatrutide in 2026: The Triple Agonist's Real Science — and Why the 'Peptide' Versions Are a Different Product Entirely
Retatrutide searches are up 150% on trial results approaching 24% average weight loss — but the drug is not approved, not compoundable, and everything sold under its name today is gray-market research chemical. The phase 2 data read honestly, the timeline, and the bright line buyers keep crossing.
Updated 2026-08-11
Semaglutide and Alcohol: What the Craving Research Actually Shows, and What Drinking on a GLP-1 Does
'Semaglutide impact on drinking' is a breakout search for a reason: trial and real-world evidence increasingly shows reduced alcohol craving and intake on GLP-1s. The research read honestly, the practical effects of drinking during treatment, who needs extra caution, and what none of this licenses.
Updated 2026-08-11
GLP-1 Microdosing in 2026: What $149 Tiers Are Selling, and What the Evidence Actually Supports
Gala sells microdosing at $149, Enhance MD tirzepatide microdosing at $169, and the search volume keeps climbing — but 'microdosing' has no trial behind it. What the tiers actually are, the three arguments made for them, what the dose-response data really shows, and the questions to ask before paying for less.
Updated 2026-08-11
What Happens When You Stop a GLP-1: The Regain Data From SURMOUNT-4 and STEP-1, Read Straight
The withdrawal trials are unambiguous: stop tirzepatide and average regain runs about 14% of body weight within a year; stop semaglutide and roughly two-thirds of lost weight returns. What the trials actually did, why regain happens, the strategies with evidence behind them, and how to price a multi-year reality honestly.
Updated 2026-08-11
Hallandale Pharmacy and Your GLP-1: How to Actually Vet a Compounding Pharmacy, Worked Example
Hallandale Pharmacy searches are up 80% because it fills GLP-1 prescriptions for major telehealth programs, including NexLife's named network. Rather than a puff piece, here's the five-check vetting process any buyer can run in fifteen minutes — license lookups, FDA inspection records, 503A status, accreditation, and the COA request — using Hallandale as the worked example.
Updated 2026-08-11
Tirzepatide Side Effects, Week by Week: What the First Twelve Weeks Usually Feel Like
In the trials, roughly a quarter to a third of tirzepatide patients had nausea and about one in five had diarrhea — overwhelmingly mild to moderate, clustered around dose escalations, fading with time. The realistic week-by-week timeline, the management that works, and the specific symptoms that mean call your clinician now.
Updated 2026-08-11
GLP-1s in California (2026): Who Actually Ships Here, the Two Licenses That Matter, and Current Prices
California telehealth GLP-1 care requires two things most buyers never verify: a prescriber licensed in California and a pharmacy holding a California license. Which tracked programs serve the state, the one major program that historically hasn't, the verification lookups, and the price floors that apply here like everywhere.
Updated 2026-08-11
The Teaser Index: Advertised vs True GLP-1 Prices Across 37 Programs, Measured
Original analysis from our database: the gap between the price in the ad and the all-in figure you actually pay. The five mechanisms that create the gap, the widest spreads in the market measured in words — TMates' 78%, Found's 71%, ShedRx's 45% — the programs where the ad and the checkout match, and the one-line defense.
Updated 2026-08-11
Oral Semaglutide in 2026: The $149 Wegovy Tablet, the Absorption Rules, and Why the $99 Sublinguals Aren't the Same Thing
FDA-approved semaglutide now comes as a daily tablet from $149 a month at NovoCare — the cheapest approved GLP-1 in existence — with strict absorption rules that decide whether it works. How the tablet compares to the pen, what the oral trial program showed, and the honest difference between this and the compounded sublingual products advertised at $99.
Updated 2026-08-11
GLP-1s in Texas (2026): Who Ships Here, the Two License Checks, and Current Prices
Texas telehealth GLP-1 care requires a Texas-licensed prescriber and a Texas-licensed pharmacy — both verifiable in minutes. Which tracked programs serve the state, the availability exceptions, the Texas State Board of Pharmacy lookup, and the price floors that apply here like everywhere.
Updated 2026-08-11
GLP-1s in Florida (2026): Who Ships Here, the Two License Checks, and Current Prices
Florida telehealth GLP-1 care requires a Florida-licensed prescriber and a Florida-licensed pharmacy — both verifiable in minutes. Which tracked programs serve the state, the availability exceptions, the Florida Board of Pharmacy lookup, and the price floors that apply here like everywhere.
Updated 2026-08-11
GLP-1s in New York (2026): Who Ships Here, the Two License Checks, and Current Prices
New York telehealth GLP-1 care requires a New York-licensed prescriber and a New York-licensed pharmacy — both verifiable in minutes. Which tracked programs serve the state, the availability exceptions, the New York State Education Department, Office of the Professions lookup, and the price floors that apply here like everywhere.
Updated 2026-08-11
GLP-1s in Pennsylvania (2026): Who Ships Here, the Two License Checks, and Current Prices
Pennsylvania telehealth GLP-1 care requires a Pennsylvania-licensed prescriber and a Pennsylvania-licensed pharmacy — both verifiable in minutes. Which tracked programs serve the state, the availability exceptions, the Pennsylvania State Board of Pharmacy lookup, and the price floors that apply here like everywhere.
Updated 2026-08-11
GLP-1s in Illinois (2026): Who Ships Here, the Two License Checks, and Current Prices
Illinois telehealth GLP-1 care requires a Illinois-licensed prescriber and a Illinois-licensed pharmacy — both verifiable in minutes. Which tracked programs serve the state, the availability exceptions, the Illinois Department of Financial and Professional Regulation lookup, and the price floors that apply here like everywhere.
Updated 2026-08-11
GLP-1s in Ohio (2026): Who Ships Here, the Two License Checks, and Current Prices
Ohio telehealth GLP-1 care requires a Ohio-licensed prescriber and a Ohio-licensed pharmacy — both verifiable in minutes. Which tracked programs serve the state, the availability exceptions, the State of Ohio Board of Pharmacy lookup, and the price floors that apply here like everywhere.
Updated 2026-08-11
GLP-1s in Georgia (2026): Who Ships Here, the Two License Checks, and Current Prices
Georgia telehealth GLP-1 care requires a Georgia-licensed prescriber and a Georgia-licensed pharmacy — both verifiable in minutes. Which tracked programs serve the state, the availability exceptions, the Georgia Board of Pharmacy lookup, and the price floors that apply here like everywhere.
Updated 2026-08-11
GLP-1s in North Carolina (2026): Who Ships Here, the Two License Checks, and Current Prices
North Carolina telehealth GLP-1 care requires a North Carolina-licensed prescriber and a North Carolina-licensed pharmacy — both verifiable in minutes. Which tracked programs serve the state, the availability exceptions, the North Carolina Board of Pharmacy lookup, and the price floors that apply here like everywhere.
Updated 2026-08-11
GLP-1s in Michigan (2026): Who Ships Here, the Two License Checks, and Current Prices
Michigan telehealth GLP-1 care requires a Michigan-licensed prescriber and a Michigan-licensed pharmacy — both verifiable in minutes. Which tracked programs serve the state, the availability exceptions, the Michigan Department of Licensing and Regulatory Affairs lookup, and the price floors that apply here like everywhere.
Updated 2026-08-11
Empower Pharmacy and Your GLP-1: The Houston Giant, Vetted the Same Way as Everyone Else
Empower Pharmacy — Houston-based, one of NexLife's five named partners, and one of the largest names in US compounding — fills a meaningful share of this market's GLP-1 prescriptions. The same five-check vetting process applied: licenses, FDA records, the 503A/503B distinction Empower makes unusually relevant, accreditation, and the COA question.
Updated 2026-08-11
Absolute, Red Rock, and Strive: Vetting the Rest of NexLife's Named Pharmacy Network
NexLife discloses five 503A partners; Hallandale and Empower have their own deep-dives, and this page runs the same public-records process across the other three — Absolute Pharmacy, Red Rock Pharmacy, and Strive Pharmacy — plus the question of which one actually fills your prescription.
Updated 2026-08-11
Tirzepatide Plateaus: Why the Scale Stops, and the Five Options That Actually Exist
Every weight-loss curve flattens — SURMOUNT-1's own averages were leveling by trial's end near 21%. Why plateaus are physiology rather than failure, how to tell a true plateau from a two-week stall, and the five real options: adherence audit, dose headroom, lifestyle re-anchor, class switch, or declaring victory.
Updated 2026-08-11
Switching From Semaglutide to Tirzepatide: How It's Actually Done, and What It Costs
There is no validated conversion chart — prescribers switch by stopping one, starting the other at or near its starting dose, and re-titrating. Why the restart is the method, what the trials say you can expect from the move, the washout question, and the $40–$270 monthly price change that comes with it.
Updated 2026-08-11
Does Tirzepatide Cause Headaches? What the Trials Recorded, and the Three Fixable Causes
Headache shows up in tirzepatide's trial data at modest single-digit rates — real, but usually downstream of three fixable things: dehydration from GI effects, an aggressive calorie drop, and abandoned caffeine. The evidence, the fixes, and the headache patterns that warrant a call instead of a glass of water.
Updated 2026-08-11
Tirzepatide, Gallbladder Disease, and Pancreatitis: The Two Warnings Worth Understanding Precisely
Both risks sit on the label; neither is common. Gallstone events tracked in the low single digits in trials — largely a rapid-weight-loss effect any method shares — and pancreatitis remains rare with a symptom signature worth memorizing. The mechanisms, the honest rates, who carries extra risk, and the exact symptoms that mean stop and call.
Updated 2026-08-11
Muscle Loss on GLP-1s: What the DXA Data Shows, and the Two-Lever Defense That Works
In body-composition substudies, roughly a quarter to two-fifths of GLP-1 weight loss was lean mass — normal for major weight loss, and defensible. Why lean mass is the variable that decides your maintenance metabolism, the protein and resistance-training levers with actual evidence, and how to tell if you're losing the wrong kind of weight.
Updated 2026-08-11
GLP-1 Injection Technique: Sites, Rotation, and the Vial-and-Syringe Skills Compounded Programs Assume
The label-standard basics — abdomen, thigh, or upper arm; rotate sites; subcutaneous, any time of day — plus the part compounded programs assume you'll figure out: drawing from a multi-dose vial, air bubbles, needle hygiene, and sharps disposal. What your pharmacy should teach, and the errors the FDA's report file exists because of.
Updated 2026-08-11
Missed a GLP-1 Dose? The 4-Day and 5-Day Rules, and Every Calendar Case That Follows
The labels are specific: a missed tirzepatide dose can be taken within 4 days (96 hours), semaglutide within 5 — after that, skip and resume; never double. The day-change minimums, what happens after two or more missed weeks, the LillyDirect 45-day pricing trap that stacks on top, and the restart conversation.
Updated 2026-08-11
GLP-1s for Women: The Side-Effect Data, the Tirzepatide Birth-Control Rule, and the Fertility Timing Question
Women report GI side effects at somewhat higher rates in trial and real-world data — and one label instruction is women-specific and widely missed: tirzepatide reduces oral contraceptive reliability during startup and escalations, and the label says add a backup method. The evidence, the four-week backup rule, the 'Ozempic babies' mechanism, and pre-pregnancy planning.
Updated 2026-08-11
Why Compounded GLP-1s Come With B12 (or Glycine): What the Additives Do, and What They Don't
Compounded semaglutide and tirzepatide routinely ship blended with vitamin B12, or with glycine and B6 — and the marketing implies energy and enhanced results. The real reasons are duller: formulation, tolerability claims, and the post-shortage regulatory logic of not being an exact copy. What each additive plausibly does, and the claim with no evidence behind it.
Updated 2026-08-11
Semaglutide Clinic Near Me vs Telehealth: What the In-Person Premium Buys, Measured Against the Floors
Local med-spa and clinic GLP-1 programs commonly price at a multiple of the telehealth floors — and sometimes earn it. What in-person genuinely adds (labs, body composition, hands-on titration), what it usually doesn't (a different medication), the questions that expose a markup wearing a lab coat, and when local actually wins.
Updated 2026-08-11
GoodRx and GLP-1s: Where Discount Cards Actually Help (Hint: Not Where You're Pointing Them)
Discount cards barely dent brand GLP-1 prices — the manufacturer programs (LillyDirect's $299–$449, NovoCare's $149–$349, the $25 savings cards) are the real levers, and compounded programs are flat cash prices a coupon can't touch. Where GoodRx genuinely earns its place: the adjunct prescriptions around your GLP-1.
Updated 2026-08-11
Buying Semaglutide From Canada: The Import Rules, the Counterfeit Record, and the Math That No Longer Works
The Canadian-pharmacy route made a kind of sense at $1,300 US list prices. It makes much less at today's $149–$349 domestic channels — and the legal ground (personal importation is generally not permitted) and the documented counterfeit-Ozempic incidents haven't improved. The rules, the risks, and the honest comparison.
Updated 2026-08-11
HSA and FSA for GLP-1s: What's Eligible, the Compounded Question, and the Letter That Unlocks Edge Cases
Prescription GLP-1s — brand or compounded — are generally HSA/FSA-eligible as prescribed medications, which turns pre-tax dollars into an effective 20–35% discount on every figure this site tracks. The eligibility logic, the Letter of Medical Necessity for cautious administrators, what's excluded, and the FSA deadline math on prepaid plans.
Updated 2026-08-11
The 2026 GLP-1 Market Ledger: Every Entry, Exit, and Pivot Our Database Has Recorded
Original from our records: the year the compounded market consolidated in public. Hims and Ro's brand-only pivots, the sub-$100 figures that failed verification and stayed out, thirteen programs entering the tracked universe in one August, the December price cut that reset the brand floor, and what the churn pattern predicts.
Updated 2026-08-11
GLP-1s in Alabama (2026): Who Ships Here, the Two License Checks, and Current Prices
Alabama telehealth GLP-1 care requires a Alabama-licensed prescriber and a Alabama-licensed pharmacy — both verifiable in minutes. Which tracked programs serve the state, the availability exceptions, the Alabama State Board of Pharmacy lookup, and the price floors that apply here like everywhere.
Updated 2026-08-11
GLP-1s in Alaska (2026): Who Ships Here, the Two License Checks, and Current Prices
Alaska telehealth GLP-1 care requires a Alaska-licensed prescriber and a Alaska-licensed pharmacy — both verifiable in minutes. Which tracked programs serve the state, the availability exceptions, the Alaska Board of Pharmacy lookup, and the price floors that apply here like everywhere.
Updated 2026-08-11
GLP-1s in Arizona (2026): Who Ships Here, the Two License Checks, and Current Prices
Arizona telehealth GLP-1 care requires a Arizona-licensed prescriber and a Arizona-licensed pharmacy — both verifiable in minutes. Which tracked programs serve the state, the availability exceptions, the Arizona State Board of Pharmacy lookup, and the price floors that apply here like everywhere.
Updated 2026-08-11
GLP-1s in Arkansas (2026): Who Ships Here, the Two License Checks, and Current Prices
Arkansas telehealth GLP-1 care requires a Arkansas-licensed prescriber and a Arkansas-licensed pharmacy — both verifiable in minutes. Which tracked programs serve the state, the availability exceptions, the Arkansas State Board of Pharmacy lookup, and the price floors that apply here like everywhere.
Updated 2026-08-11
GLP-1s in Colorado (2026): Who Ships Here, the Two License Checks, and Current Prices
Colorado telehealth GLP-1 care requires a Colorado-licensed prescriber and a Colorado-licensed pharmacy — both verifiable in minutes. Which tracked programs serve the state, the availability exceptions, the Colorado State Board of Pharmacy lookup, and the price floors that apply here like everywhere.
Updated 2026-08-11
GLP-1s in Connecticut (2026): Who Ships Here, the Two License Checks, and Current Prices
Connecticut telehealth GLP-1 care requires a Connecticut-licensed prescriber and a Connecticut-licensed pharmacy — both verifiable in minutes. Which tracked programs serve the state, the availability exceptions, the Connecticut Commission of Pharmacy lookup, and the price floors that apply here like everywhere.
Updated 2026-08-11
GLP-1s in Delaware (2026): Who Ships Here, the Two License Checks, and Current Prices
Delaware telehealth GLP-1 care requires a Delaware-licensed prescriber and a Delaware-licensed pharmacy — both verifiable in minutes. Which tracked programs serve the state, the availability exceptions, the Delaware Board of Pharmacy lookup, and the price floors that apply here like everywhere.
Updated 2026-08-11
GLP-1s in Hawaii (2026): Who Ships Here, the Two License Checks, and Current Prices
Hawaii telehealth GLP-1 care requires a Hawaii-licensed prescriber and a Hawaii-licensed pharmacy — both verifiable in minutes. Which tracked programs serve the state, the availability exceptions, the Hawaii Board of Pharmacy lookup, and the price floors that apply here like everywhere.
Updated 2026-08-11
GLP-1s in Idaho (2026): Who Ships Here, the Two License Checks, and Current Prices
Idaho telehealth GLP-1 care requires a Idaho-licensed prescriber and a Idaho-licensed pharmacy — both verifiable in minutes. Which tracked programs serve the state, the availability exceptions, the Idaho Board of Pharmacy lookup, and the price floors that apply here like everywhere.
Updated 2026-08-11
GLP-1s in Indiana (2026): Who Ships Here, the Two License Checks, and Current Prices
Indiana telehealth GLP-1 care requires a Indiana-licensed prescriber and a Indiana-licensed pharmacy — both verifiable in minutes. Which tracked programs serve the state, the availability exceptions, the Indiana Board of Pharmacy lookup, and the price floors that apply here like everywhere.
Updated 2026-08-11
GLP-1s in Iowa (2026): Who Ships Here, the Two License Checks, and Current Prices
Iowa telehealth GLP-1 care requires a Iowa-licensed prescriber and a Iowa-licensed pharmacy — both verifiable in minutes. Which tracked programs serve the state, the availability exceptions, the Iowa Board of Pharmacy lookup, and the price floors that apply here like everywhere.
Updated 2026-08-11
GLP-1s in Kansas (2026): Who Ships Here, the Two License Checks, and Current Prices
Kansas telehealth GLP-1 care requires a Kansas-licensed prescriber and a Kansas-licensed pharmacy — both verifiable in minutes. Which tracked programs serve the state, the availability exceptions, the Kansas Board of Pharmacy lookup, and the price floors that apply here like everywhere.
Updated 2026-08-11
GLP-1s in Kentucky (2026): Who Ships Here, the Two License Checks, and Current Prices
Kentucky telehealth GLP-1 care requires a Kentucky-licensed prescriber and a Kentucky-licensed pharmacy — both verifiable in minutes. Which tracked programs serve the state, the availability exceptions, the Kentucky Board of Pharmacy lookup, and the price floors that apply here like everywhere.
Updated 2026-08-11
GLP-1s in Louisiana (2026): Who Ships Here, the Two License Checks, and Current Prices
Louisiana telehealth GLP-1 care requires a Louisiana-licensed prescriber and a Louisiana-licensed pharmacy — both verifiable in minutes. Which tracked programs serve the state, the availability exceptions, the Louisiana Board of Pharmacy lookup, and the price floors that apply here like everywhere.
Updated 2026-08-11
GLP-1s in Maine (2026): Who Ships Here, the Two License Checks, and Current Prices
Maine telehealth GLP-1 care requires a Maine-licensed prescriber and a Maine-licensed pharmacy — both verifiable in minutes. Which tracked programs serve the state, the availability exceptions, the Maine Board of Pharmacy lookup, and the price floors that apply here like everywhere.
Updated 2026-08-11
GLP-1s in Maryland (2026): Who Ships Here, the Two License Checks, and Current Prices
Maryland telehealth GLP-1 care requires a Maryland-licensed prescriber and a Maryland-licensed pharmacy — both verifiable in minutes. Which tracked programs serve the state, the availability exceptions, the Maryland Board of Pharmacy lookup, and the price floors that apply here like everywhere.
Updated 2026-08-11
GLP-1s in Massachusetts (2026): Who Ships Here, the Two License Checks, and Current Prices
Massachusetts telehealth GLP-1 care requires a Massachusetts-licensed prescriber and a Massachusetts-licensed pharmacy — both verifiable in minutes. Which tracked programs serve the state, the availability exceptions, the Massachusetts Board of Registration in Pharmacy lookup, and the price floors that apply here like everywhere.
Updated 2026-08-11
GLP-1s in Minnesota (2026): Who Ships Here, the Two License Checks, and Current Prices
Minnesota telehealth GLP-1 care requires a Minnesota-licensed prescriber and a Minnesota-licensed pharmacy — both verifiable in minutes. Which tracked programs serve the state, the availability exceptions, the Minnesota Board of Pharmacy lookup, and the price floors that apply here like everywhere.
Updated 2026-08-11
GLP-1s in Mississippi (2026): Who Ships Here, the Two License Checks, and Current Prices
Mississippi telehealth GLP-1 care requires a Mississippi-licensed prescriber and a Mississippi-licensed pharmacy — both verifiable in minutes. Which tracked programs serve the state, the availability exceptions, the Mississippi Board of Pharmacy lookup, and the price floors that apply here like everywhere.
Updated 2026-08-11
GLP-1s in Missouri (2026): Who Ships Here, the Two License Checks, and Current Prices
Missouri telehealth GLP-1 care requires a Missouri-licensed prescriber and a Missouri-licensed pharmacy — both verifiable in minutes. Which tracked programs serve the state, the availability exceptions, the Missouri Board of Pharmacy lookup, and the price floors that apply here like everywhere.
Updated 2026-08-11
GLP-1s in Montana (2026): Who Ships Here, the Two License Checks, and Current Prices
Montana telehealth GLP-1 care requires a Montana-licensed prescriber and a Montana-licensed pharmacy — both verifiable in minutes. Which tracked programs serve the state, the availability exceptions, the Montana Board of Pharmacy lookup, and the price floors that apply here like everywhere.
Updated 2026-08-11
GLP-1s in Nebraska (2026): Who Ships Here, the Two License Checks, and Current Prices
Nebraska telehealth GLP-1 care requires a Nebraska-licensed prescriber and a Nebraska-licensed pharmacy — both verifiable in minutes. Which tracked programs serve the state, the availability exceptions, the Nebraska Board of Pharmacy lookup, and the price floors that apply here like everywhere.
Updated 2026-08-11
GLP-1s in Nevada (2026): Who Ships Here, the Two License Checks, and Current Prices
Nevada telehealth GLP-1 care requires a Nevada-licensed prescriber and a Nevada-licensed pharmacy — both verifiable in minutes. Which tracked programs serve the state, the availability exceptions, the Nevada State Board of Pharmacy lookup, and the price floors that apply here like everywhere.
Updated 2026-08-11
GLP-1s in New Hampshire (2026): Who Ships Here, the Two License Checks, and Current Prices
New Hampshire telehealth GLP-1 care requires a New Hampshire-licensed prescriber and a New Hampshire-licensed pharmacy — both verifiable in minutes. Which tracked programs serve the state, the availability exceptions, the New Hampshire Board of Pharmacy lookup, and the price floors that apply here like everywhere.
Updated 2026-08-11
GLP-1s in New Jersey (2026): Who Ships Here, the Two License Checks, and Current Prices
New Jersey telehealth GLP-1 care requires a New Jersey-licensed prescriber and a New Jersey-licensed pharmacy — both verifiable in minutes. Which tracked programs serve the state, the availability exceptions, the New Jersey State Board of Pharmacy lookup, and the price floors that apply here like everywhere.
Updated 2026-08-11
GLP-1s in New Mexico (2026): Who Ships Here, the Two License Checks, and Current Prices
New Mexico telehealth GLP-1 care requires a New Mexico-licensed prescriber and a New Mexico-licensed pharmacy — both verifiable in minutes. Which tracked programs serve the state, the availability exceptions, the New Mexico Board of Pharmacy lookup, and the price floors that apply here like everywhere.
Updated 2026-08-11
GLP-1s in North Dakota (2026): Who Ships Here, the Two License Checks, and Current Prices
North Dakota telehealth GLP-1 care requires a North Dakota-licensed prescriber and a North Dakota-licensed pharmacy — both verifiable in minutes. Which tracked programs serve the state, the availability exceptions, the North Dakota State Board of Pharmacy lookup, and the price floors that apply here like everywhere.
Updated 2026-08-11
GLP-1s in Oklahoma (2026): Who Ships Here, the Two License Checks, and Current Prices
Oklahoma telehealth GLP-1 care requires a Oklahoma-licensed prescriber and a Oklahoma-licensed pharmacy — both verifiable in minutes. Which tracked programs serve the state, the availability exceptions, the Oklahoma State Board of Pharmacy lookup, and the price floors that apply here like everywhere.
Updated 2026-08-11
GLP-1s in Oregon (2026): Who Ships Here, the Two License Checks, and Current Prices
Oregon telehealth GLP-1 care requires a Oregon-licensed prescriber and a Oregon-licensed pharmacy — both verifiable in minutes. Which tracked programs serve the state, the availability exceptions, the Oregon Board of Pharmacy lookup, and the price floors that apply here like everywhere.
Updated 2026-08-11
GLP-1s in Rhode Island (2026): Who Ships Here, the Two License Checks, and Current Prices
Rhode Island telehealth GLP-1 care requires a Rhode Island-licensed prescriber and a Rhode Island-licensed pharmacy — both verifiable in minutes. Which tracked programs serve the state, the availability exceptions, the Rhode Island Board of Pharmacy lookup, and the price floors that apply here like everywhere.
Updated 2026-08-11
GLP-1s in South Carolina (2026): Who Ships Here, the Two License Checks, and Current Prices
South Carolina telehealth GLP-1 care requires a South Carolina-licensed prescriber and a South Carolina-licensed pharmacy — both verifiable in minutes. Which tracked programs serve the state, the availability exceptions, the South Carolina Board of Pharmacy lookup, and the price floors that apply here like everywhere.
Updated 2026-08-11
GLP-1s in South Dakota (2026): Who Ships Here, the Two License Checks, and Current Prices
South Dakota telehealth GLP-1 care requires a South Dakota-licensed prescriber and a South Dakota-licensed pharmacy — both verifiable in minutes. Which tracked programs serve the state, the availability exceptions, the South Dakota State Board of Pharmacy lookup, and the price floors that apply here like everywhere.
Updated 2026-08-11
GLP-1s in Tennessee (2026): Who Ships Here, the Two License Checks, and Current Prices
Tennessee telehealth GLP-1 care requires a Tennessee-licensed prescriber and a Tennessee-licensed pharmacy — both verifiable in minutes. Which tracked programs serve the state, the availability exceptions, the Tennessee Board of Pharmacy lookup, and the price floors that apply here like everywhere.
Updated 2026-08-11
GLP-1s in Utah (2026): Who Ships Here, the Two License Checks, and Current Prices
Utah telehealth GLP-1 care requires a Utah-licensed prescriber and a Utah-licensed pharmacy — both verifiable in minutes. Which tracked programs serve the state, the availability exceptions, the Utah Division of Professional Licensing lookup, and the price floors that apply here like everywhere.
Updated 2026-08-11
GLP-1s in Vermont (2026): Who Ships Here, the Two License Checks, and Current Prices
Vermont telehealth GLP-1 care requires a Vermont-licensed prescriber and a Vermont-licensed pharmacy — both verifiable in minutes. Which tracked programs serve the state, the availability exceptions, the Vermont Board of Pharmacy lookup, and the price floors that apply here like everywhere.
Updated 2026-08-11
GLP-1s in Virginia (2026): Who Ships Here, the Two License Checks, and Current Prices
Virginia telehealth GLP-1 care requires a Virginia-licensed prescriber and a Virginia-licensed pharmacy — both verifiable in minutes. Which tracked programs serve the state, the availability exceptions, the Virginia Board of Pharmacy lookup, and the price floors that apply here like everywhere.
Updated 2026-08-11
GLP-1s in Washington (2026): Who Ships Here, the Two License Checks, and Current Prices
Washington telehealth GLP-1 care requires a Washington-licensed prescriber and a Washington-licensed pharmacy — both verifiable in minutes. Which tracked programs serve the state, the availability exceptions, the Washington Pharmacy Quality Assurance Commission lookup, and the price floors that apply here like everywhere.
Updated 2026-08-11
GLP-1s in West Virginia (2026): Who Ships Here, the Two License Checks, and Current Prices
West Virginia telehealth GLP-1 care requires a West Virginia-licensed prescriber and a West Virginia-licensed pharmacy — both verifiable in minutes. Which tracked programs serve the state, the availability exceptions, the West Virginia Board of Pharmacy lookup, and the price floors that apply here like everywhere.
Updated 2026-08-11
GLP-1s in Wisconsin (2026): Who Ships Here, the Two License Checks, and Current Prices
Wisconsin telehealth GLP-1 care requires a Wisconsin-licensed prescriber and a Wisconsin-licensed pharmacy — both verifiable in minutes. Which tracked programs serve the state, the availability exceptions, the Wisconsin Pharmacy Examining Board lookup, and the price floors that apply here like everywhere.
Updated 2026-08-11
GLP-1s in Wyoming (2026): Who Ships Here, the Two License Checks, and Current Prices
Wyoming telehealth GLP-1 care requires a Wyoming-licensed prescriber and a Wyoming-licensed pharmacy — both verifiable in minutes. Which tracked programs serve the state, the availability exceptions, the Wyoming State Board of Pharmacy lookup, and the price floors that apply here like everywhere.
Updated 2026-08-11
GLP-1s in Washington, D.C. (2026): Who Ships Here, the Two License Checks, and Current Prices
D.C. telehealth GLP-1 care requires a D.C.-licensed prescriber and a D.C.-licensed pharmacy — both verifiable on the District's health-licensing portal. The footprint nuance most lists miss (Henry's '41 states' count is built from the 50 states, leaving D.C. to confirm), plus the price floors that apply here like everywhere.
Updated 2026-08-11
Henry Meds Review 2026: The $179 Flat Benchmark, Audited
Henry Meds is the market's reference point: $179 a month flat for compounded tirzepatide or semaglutide, every dose, all-inclusive, across 41 states — corroborated by two independent 2026 sources. The full audit: what flat really includes, the unnamed-pharmacy gap, the corrected price history, and who beats it.
Updated 2026-08-11
bmiMD Review 2026: The Semaglutide Price Leader's Full Ladder, Audited
bmiMD holds the semaglutide crown on our computed rankings — $129 month-to-month down to $99 on twelve months, same price at every dose — and ties the tirzepatide twelve-month floor at $139. The audit: the term-ladder fine print, the named-pharmacy claim to confirm, and exactly where it wins and loses.
Updated 2026-08-11
Trimi Review 2026: The $99/$125 Annual Plans, and the $1,500 Question
Trimi holds the lowest annual-equivalent prices in the market — $99 a month semaglutide, $125 tirzepatide — with one defining catch: the entire year bills upfront ($1,188 / $1,500), and no month-to-month rate is published. The audit: what the structure means, the refund clause that is the real price, and who should and shouldn't take the deal.
Updated 2026-08-11
HealthRX Review 2026: $99 Semaglutide With a Term Ladder and No Monthly Option
HealthRX co-holds the $99 twelve-month semaglutide floor and posts $179 twelve-month tirzepatide — flat at every dose, billed monthly — with one structural quirk: no month-to-month plan exists, so the shortest commitment is three months at $133/$209. The audit of what that shape means and where it ranks.
Updated 2026-08-11
Yucca Health Review 2026: The $146 'For Life' Promo, Decoded
Yucca advertises the market's catchiest offer — '$146/mo for life' semaglutide under promo code YUCCA4LIFE — and the fine print does real work: new-patient six-month-plan entry rate, tirzepatide at $258, full pricing gated behind intake, pharmacies unnamed. The decode, the questions, and where it actually ranks.
Updated 2026-08-11
Mochi Health Review 2026: $278 All-In for the Most Programming, in the Fewest States
Mochi bundles the most clinical programming in the compounded market — dietitians, labs, structured curriculum — atop a $79 membership plus $199 tirzepatide, for $278 all-in ($178 semaglutide), across only ~10 states. The audit: what the premium buys, the membership math, and who it genuinely fits.
Updated 2026-08-11
Ivim Health Review 2026: The $75 Membership Model, All-In at $149 Sema / $278 Tirz
Ivim runs the membership structure with a lighter touch than Mochi: $75 monthly membership, all-in figures of about $149 for semaglutide and $278 for tirzepatide. The audit: where the semaglutide number is quietly competitive, where the tirzepatide number isn't, and the membership questions that decide it.
Updated 2026-08-11
Found Review 2026: $169 Prepaid or $289 Monthly, and the Prescriber-Chooses Caveat
Found prices both molecules identically — $169 a month on a prepaid twelve-month plan, $289 month-to-month — with an insurance track from $99, and one caveat its ads underplay: the clinician may prescribe something other than a GLP-1. The audit of the structure, the 71% prepay spread, and who it fits.
Updated 2026-08-11
Eden Review 2026: The Widest Footprint, an In-House Pharmacy, and Gated Prices
Eden's structural story is unique: roughly fifty-state coverage and its own compounding pharmacy — Contigo, acquired August 2025 — with the trade-off that pricing largely lives behind intake; our records carry provider-stated figures around $198 semaglutide and $408 tirzepatide. The audit of vertical integration, and the transparency test it sets up.
Updated 2026-08-11
TMates Review 2026: The $158 Headline and the 78% Spread Behind It
TMates advertises from $158 a month — the compounded semaglutide twelve-month rate — while month-to-month runs $249, and tirzepatide runs $167 committed against $297 monthly, the widest spread in our Teaser Index. The audit of what's included, and who the committed rates genuinely fit.
Updated 2026-08-11
Gala GLP-1 Review 2026: The $149–$199 Range, and Why 'Confirm in Enrollment' Is the Price
Gala publishes a range rather than a rate — $179 standard 'all doses,' $199 on a three-month plan, $149 microdosing — across an all-fifty-state claim. The audit: what each figure means, the microdosing tier read against the evidence, and the one enrollment question that sets your actual number.
Updated 2026-08-11
Luvo Health Review 2026: 52-Week Math, Four Named Pharmacies, and the Testing Question
Luvo publishes term totals in weeks — $2,327 for a year of semaglutide ($194/mo equivalent), $3,497 tirzepatide ($291) — with $249/$339 four-week no-commitment rates, four named dispensing pharmacies, and, per an August 2026 audit, no stated 503A/B status or third-party testing claim. The full decode.
Updated 2026-08-11
Direct Meds Review 2026: Format-Priced From $249 to $399, All-Inclusive and Verified First-Party
Direct Meds prices by format — semaglutide from $249 sublingual to $297 injection, tirzepatide from $299 to $399 — with 'billed every month, 0% off' first-party clarity and no plan gymnastics. The audit: what format pricing means, the sublingual caveat, and where honest-but-high lands.
Updated 2026-08-11
Care Bare Rx Review 2026: $199 Flat, Both Molecules, Lighter Touch
Care Bare Rx runs the simplest sentence after Henry's: $199 a month, semaglutide or tirzepatide, month-to-month, ad matching checkout — with a lighter clinical model our records flag for refill-cadence and prescriber-access questions. Short structure, short review.
Updated 2026-08-11
Strut Health Review 2026: The $99 Entry That Can't Be Ranked, Explained
Strut advertises the market's lowest semaglutide number of any kind — $99 sublingual, $149 injectable — as lowest-dose auto-refill starting prices with no published maintenance rate, plus a tirzepatide lozenge gated behind injectable failure. Why our methodology records it without ranking it, and the questions that would change that.
Updated 2026-08-11
Synergy Rx Review 2026: '$199 Starting' Under a Promo Banner, Decoded
Synergy Rx advertises injectable semaglutide 'starting at $199' and tirzepatide at $349 beneath a live '2026 Promo Applied' banner and $100 welcome credit — classic promo-plus-start anchoring across an all-fifty-state claim with advertised named pharmacies. The decode and the enrollment questions.
Updated 2026-08-11
Enhance MD Review 2026: Bundled Metabolic Programs From $212, Priced as Programs
Enhance MD sells tiers, not vials: 'GLP-1 Core' semaglutide at $212 ($112 first month), tirzepatide 'Advanced' at $280, combo 'Elite' at $322, microdosed tirzepatide at $169 — each bundling provider care and six-month metabolic labs. The audit prices the program as a program.
Updated 2026-08-11
Sprout Health Review 2026: Homepage Prices, Funnel Rates, and the Brand Sticker Shock
Sprout advertises 'starting at' $149 semaglutide and $199 tirzepatide on its homepage — with the final rate personalized in the signup funnel, and brand options captured near $1,799 Wegovy and $1,999 Zepbound. Why the row is recorded not ranked, and what the funnel must answer.
Updated 2026-08-11
LumiMeds Review 2026: The Other $125 Tirzepatide, on the Thinnest Sourcing We Track
LumiMeds ties Trimi at the tirzepatide annual floor — $125 a month on a $1,500 upfront twelve-month plan, $140 on six months — with no semaglutide, no month-to-month rate, and a status honestly labeled: reported from a community-sourced capture, first-party verification pending. The audit of a floor price on thin evidence.
Updated 2026-08-11
ShedRx Review 2026: Four Formats, a 45% Dose Spread, and an Affiliate First-Month Discount
ShedRx runs the market's widest format menu — injections, lozenges, drops, oral tablets — with tirzepatide starting near $199 and maintaining near $289, semaglutide injection from $249, and a 30%-off first month via affiliate links. The audit of the menu, the spread, and the promo plumbing.
Updated 2026-08-11
SkinnyRx Review 2026: $199/$299, Ad Matching Checkout, Mid-Tier by Choice
SkinnyRx keeps it stated: $199 semaglutide, $299 tirzepatide, provider-stated, with the advertised price surviving to checkout. A short review for a legible program — where it lands, what the premium over the floor buys, and the one question left.
Updated 2026-08-11
OrderlyMeds Review 2026: $149 Semaglutide That Competes, $299 Tirzepatide That Doesn't
OrderlyMeds states its prices and they hold at checkout: $149 semaglutide — inside the value cluster — and $299 tirzepatide, double the flat tier. A split-verdict review: where the semaglutide number earns a shortlist spot, and the brand comparison the tirzepatide number walks into.
Updated 2026-08-11
Remedy Meds Review 2026: The $399 Question a Forbes Citation Made Famous
Remedy Meds prices compounded tirzepatide at $399 and semaglutide at $299 — figures prominent enough that answer engines cite them as the 'not among the cheapest' example. The short audit: what the premium would need to buy, and the brand math at this altitude.
Updated 2026-08-11
MEDVi Review 2026: $299/$399, and the Case That Has to Be Made at Intake
MEDVi's provider-stated rates — $299 semaglutide, $399 tirzepatide — mirror Remedy's altitude without a public service bundle to explain them. The short audit and the three questions that would justify, or fail to justify, the premium.
Updated 2026-08-11
LifeMD Review 2026: The $597 Ceiling, and What Full-Service Telehealth Costs
LifeMD holds the top of our compounded table — $597 tirzepatide, $348 semaglutide, provider-stated — as a full-service telehealth platform whose GLP-1 pricing exceeds the FDA-approved products themselves. The audit of what ceiling pricing means and who could rationally pay it.
Updated 2026-08-11
Noom Med Review 2026: $199 Semaglutide Attached to the Famous App
Noom Med bolts compounded semaglutide at $199 onto the behavior-change app that made the brand — no tirzepatide in our records. The audit: what the app layer is worth against the $129 floor, and the psychology-plus-pharmacology case read honestly.
Updated 2026-08-11
Oak Longevity Review 2026: The Quiet $133 That Almost Leads
Oak Longevity posts $133 month-to-month compounded semaglutide — four dollars from the market floor — as a small operator with an un-itemized pharmacy line. A short review of a near-leader whose remaining questions are the whole story.
Updated 2026-08-11
Fridays Review 2026: $175 Semaglutide, $359 Tirzepatide — One Competitive Lane
Fridays runs a split book: semaglutide at $175 — inside the competitive band — and tirzepatide at $359, upper-shelf territory. The short audit of a program whose two molecules argue different cases.
Updated 2026-08-11
Lavender Sky Health Review 2026: $174/$352, the Fridays Twin
Lavender Sky mirrors the split-book pattern almost to the dollar: $174 semaglutide in the competitive band, $352 tirzepatide on the upper shelf. The short audit and the tie-breaker questions against its twin.
Updated 2026-08-11
Amble Health Review 2026: A $300 Tirzepatide-Only Row, Read Plainly
Amble Health appears in our database as a single provider-stated fact: compounded tirzepatide at $300, no semaglutide. The shortest honest review we publish — placement, the questions that would fill the row, and what a thin public record should mean to a buyer.
Updated 2026-08-11
Fifty 410 Review 2026: The Famous $133 That Isn't a Price
Fifty 410's $133 tirzepatide is one of the market's most-quoted numbers — and it's a starting figure with no published maintenance rate, the textbook case behind our unrankable rule. The review of a number, and of the rule it justified.
Updated 2026-08-11
Hims & Hers GLP-1 Review 2026: The Post-Settlement, Brand-Only Storefront, Priced All-In
Since the March 9, 2026 Novo settlement, Hims & Hers sells brand GLP-1s only — Wegovy $299, oral Wegovy $249, Zepbound $399 — atop a $149 membership, for true all-ins of $448–$548. The audit of what the platform adds, and the direct-channel math it must beat.
Updated 2026-08-11
Ro Review 2026: The Insurance Concierge That Earns Its Category — and the Cash Price That Doesn't
Ro's 2026 model is brand medication plus the market's best coverage concierge — benefits checks, prior authorizations, appeals — which wins our 'best with insurance' category outright. Its cash all-ins of roughly $448–$598 are another story. Both halves, audited.
Updated 2026-08-11
LillyDirect Review 2026: The Benchmark Itself, Audited Like Everyone Else
LillyDirect's Zepbound vial program — $299/$399/$449 by dose, 45-day refill rule, no subscription — is the figure every compounded price on this site answers to. The manufacturer's channel gets the same audit: strengths, the calendar trap, and who should pay the benchmark.
Updated 2026-08-11
NovoCare Review 2026: The Semaglutide Counter — $349 Pens, $199 Intro, $149 Tablets
NovoCare is the semaglutide benchmark: Wegovy pens at $349 ($399 for the 7.2 mg tier), a $199 introduction on the first two starter fills through 2026, and oral Wegovy from $149. The manufacturer channel audited — including the tier fine print the headlines skip.
Updated 2026-08-11
Tirzepatide for Sleep Apnea: The FDA-Approved Indication Most People Don't Know Exists
Since December 2024, Zepbound is FDA-approved for moderate-to-severe obstructive sleep apnea in adults with obesity — the SURMOUNT-OSA trials cut apnea events by roughly 25–30 per hour versus about 5 on placebo, with a large share reaching remission-range severity. What the indication changes, including for insurance.
Updated 2026-08-11
GLP-1s for Type 2 Diabetes: The Original Job, the SURPASS Numbers, and the Coverage Advantage
Before the weight-loss era, these were diabetes drugs — and for T2D they remain first-tier: tirzepatide cut HbA1c by roughly 1.9–2.5 points across SURPASS with 7–12 kg weight loss. What the diabetes indication changes for treatment and, decisively, for insurance.
Updated 2026-08-11
GLP-1s and PCOS: What the Evidence Supports, What It Doesn't Yet, and the Fertility Clause
No GLP-1 carries a PCOS indication — but PCOS's metabolic core (insulin resistance, weight-responsive ovulation) sits squarely in the class's mechanism, and clinicians increasingly use them off-label. The honest evidence review, the metformin question, and the contraception warning that matters more here than anywhere.
Updated 2026-08-11
GLP-1s and Fatty Liver Disease: The MASLD Evidence, Including the Trial That Changed It
A quarter to a third of US adults carry MASLD, and this drug class now has real liver evidence: semaglutide's phase-3 MASH trial resolved steatohepatitis in roughly twice the placebo rate, and 2026 network meta-analysis work places tirzepatide among effective fibrosis interventions. The honest map of a fast-moving field.
Updated 2026-08-11
GLP-1s and Heart Health: What SELECT Proved, and Who It Changed the Math For
The SELECT trial — 17,600 adults with cardiovascular disease and overweight, no diabetes — showed semaglutide cut major cardiac events by about 20%, earning Wegovy a cardiovascular indication. What that means, who it applies to, and the second insurance door it opened.
Updated 2026-08-11
GLP-1s for Prediabetes: The Reversion Evidence, the Coverage Reality, and the Honest Alternatives
In the weight-loss trials, the large majority of participants with prediabetes reverted to normal glucose regulation on treatment — a striking, consistent finding without an FDA indication or, usually, insurance coverage behind it. The evidence, the DPP context, and the decision most prediabetic buyers actually face.
Updated 2026-08-11
GLP-1s and Metformin Together: The Most Common Combination, Explained
Metformin plus a GLP-1 is the default stack in metabolic medicine — no meaningful pharmacokinetic conflict, complementary mechanisms, additive GI effects to manage. What each does, why prescribers keep both, and the practical rules of running them together.
Updated 2026-08-11
GLP-1s With Insulin or Sulfonylureas: The One Combination That Demands Re-Dosing
GLP-1s don't cause hypoglycemia — until they're stacked on insulin or a sulfonylurea, where the labels themselves advise considering dose reductions at initiation. Why the combination lowers sugar too well, the symptoms to know cold, and the coordination rule that makes it safe.
Updated 2026-08-11
GLP-1s and Levothyroxine: The Absorption Question, and the TSH Check That Answers It
Slowed gastric emptying can change how oral medications absorb — and levothyroxine, famously fussy about absorption, is the one thyroid patients ask about most. The mechanism, the label context, the empty-stomach rules that don't change, and the follow-up TSH that settles it.
Updated 2026-08-11
GLP-1s and Antidepressants: What Actually Interacts, What Doesn't, and What to Watch
SSRIs, SNRIs, and most antidepressants have no direct pharmacokinetic conflict with GLP-1s — the real considerations are additive early nausea, appetite and weight interplay with psych-med side effects, and mood monitoring during major weight change. The map, minus the alarm.
Updated 2026-08-11
GLP-1s and Lithium: The Narrow-Window Interaction That Made the Case Reports
Lithium's tiny therapeutic window meets the GLP-1 era's fluid and intake changes: a 2026 case report documented toxicity requiring hemodialysis in a previously stable patient after starting tirzepatide. The mechanism, the monitoring protocol that prevents it, and the coordination rule with no exceptions.
Updated 2026-08-11
GLP-1s Before Surgery: The Hold-a-Week Guidance, and Why Anesthesiologists Insist
Anesthesiology guidance since 2023 directs holding weekly GLP-1s for a week before elective procedures — slowed gastric emptying means food can remain in the stomach past standard fasting windows, an aspiration risk under anesthesia. The rule, the reasons, and the conversation to have before any procedure.
Updated 2026-08-11
How to Store GLP-1 Medications: Refrigeration Rules, Room-Temperature Windows, and the Freeze Rule
Every GLP-1 lives in the refrigerator by default — with brand-specific room-temperature allowances the labels spell out (Wegovy 28 days before use, Ozempic 56 days in-use, Zepbound and Mounjaro 21 days) and one absolute: frozen product is discarded, never thawed and used. The storage map, including the compounded rule.
Updated 2026-08-11
Traveling With GLP-1s: TSA Rules, the Cold Chain, Time Zones, and the Paper to Carry
Injectable medication travels legally and easily — needles and all — in carry-on luggage, with an insulated pack solving the cold chain and the weekly schedule shrugging off time zones. The complete protocol: security, packing, international paperwork, and what never goes in checked baggage.
Updated 2026-08-11
GLP-1s and Hair Loss: The Telogen Effluvium Explanation, and What Actually Helps
Hair shedding a few months into treatment is usually telogen effluvium — the follicle cycle's stereotyped response to rapid weight loss, not a direct drug effect — and it's typically temporary. The mechanism, the timeline, the labs worth checking, and the nutrition that matters.
Updated 2026-08-11
Sulfur Burps and Reflux on GLP-1s: Why Slowed Digestion Does This, and the Fixes That Work
The infamous rotten-egg burps and new-onset reflux share one cause — food sitting longer in a slowed stomach — and mostly one solution set: smaller, lower-fat meals, upright time after eating, and titration patience. The mechanism, the fix list, and the red flags that mean call.
Updated 2026-08-11
Fatigue on GLP-1s: The Deficit Explanation, the Fixable Causes, and When to Test
Early-phase tiredness usually has boring causes — a large calorie deficit, quiet dehydration, protein shortfall, disrupted sleep — each fixable. The triage order, the adaptation timeline, and the lab panel worth running when fatigue persists past it.
Updated 2026-08-11
Exercising on GLP-1s: Fueling Training in a Deficit Without Wrecking Either
The medication creates the deficit; training decides what the lost weight is made of. How to fuel workouts when appetite is suppressed — protein anchors, deliberate carbs around sessions, hydration math — plus the dizziness rule and the program that protects muscle.
Updated 2026-08-11
Beyond-Use Dates: Why Compounded GLP-1s Expire in Weeks, Not Years
The date on a compounded vial isn't a manufacturer expiration — it's a beyond-use date assigned under USP standards, typically weeks out, reflecting sterility and stability limits of pharmacy-prepared sterile products. What BUDs mean, why they're short, and why the discard rule is absolute.
Updated 2026-08-11
Certificates of Analysis for Compounded GLP-1s: What a Real COA Shows, and How to Read One
The COA is the document that converts 'trust us' into data: identity, potency, sterility, and endotoxin results for a specific lot, ideally from an independent laboratory. What each section means, the reading checklist, and what a refusal to provide one tells you.
Updated 2026-08-11
503A vs 503B: The Two Kinds of Compounding Pharmacy, and Why the Letter Matters in 2026
Every compounded GLP-1 comes from one of two legal categories — 503A patient-specific pharmacies under state-board oversight, or 503B outsourcing facilities under FDA CGMP — and 2026's rules treat them very differently. The plain-English explainer this site's other pages lean on.
Updated 2026-08-11
How to Read a Compounded GLP-1 Label: The Seven Fields That Prevent the Serious Errors
The vial label is a dense little document that answers every dosing and safety question — if you know its seven fields: drug and salt form, concentration, BUD, storage, lot, pharmacy identity, and directions. The walkthrough, and the cross-checks that catch mistakes before injection.
Updated 2026-08-11
Ozempic vs Wegovy: Same Molecule, Different Labels — and Very Different Buying Paths
Both are Novo Nordisk's semaglutide; the differences are indication (diabetes vs obesity plus cardiovascular), dose ceilings (2 mg vs 2.4 and the newer 7.2 tier), insurance treatment, and cash channels. The practical comparison that ends the most common naming confusion in the class.
Updated 2026-08-11
Mounjaro vs Zepbound: One Tirzepatide, Two Labels, and the Channel That Matters
Lilly's tirzepatide wears two names: Mounjaro for type 2 diabetes, Zepbound for weight management and sleep apnea — same molecule, same 2.5-to-15 mg ladder. The differences that matter: indications, insurance logic, and the fact that the $299–$449 vial program is Zepbound-only.
Updated 2026-08-11
Tirzepatide 2.5 mg: The Starter Dose — What It's For, What to Expect, What It Costs
2.5 mg is tirzepatide's initiation dose: four weeks of tolerance-building, not a maintenance target. What the label says it's for, why weight results are modest by design, the $299 brand rung and $199-intro economics, and the escalation ahead.
Updated 2026-08-11
Tirzepatide 5 mg: The First Maintenance Dose — the 15% Arm, Audited
5 mg is where tirzepatide's studied results begin: 15.0% average loss at 72 weeks in SURMOUNT-1 — a full maintenance dose many patients never need to leave. What the arm showed, who stays here, the $399 brand rung, and the escalate-or-hold decision.
Updated 2026-08-11
Tirzepatide 7.5 mg: The In-Between Dose — What We Know When the Trial Didn't Study It
7.5 mg wasn't a SURMOUNT-1 arm — it's the labeled step between the 15% and 19.5% doses, where many patients land clinically. How to reason about an unstudied-but-labeled dose, the escalation echo, and the $449 price threshold it crosses.
Updated 2026-08-11
Tirzepatide 10 mg: The 19.5% Arm — Where Most of the Curve's Benefit Arrives
10 mg is the middle studied maintenance dose and arguably the efficiency point: 19.5% average loss at 72 weeks — 1.4 points shy of 15 mg with meaningfully easier tolerability. The arm's numbers, who lands here, and the hold-versus-max decision.
Updated 2026-08-11
Tirzepatide 12.5 mg: The Last Step Before Max — Reasoning Between the 19.5% and 20.9% Arms
Like 7.5, the 12.5 mg dose is labeled but wasn't a SURMOUNT-1 arm — it's the mandated staging step to 15 mg and a legitimate place to stop. The between-arms logic at the top of the ladder, where the marginal averages are smallest.
Updated 2026-08-11
Tirzepatide 15 mg: The Maximum Dose — the 20.9% Arm and the Questions at the Top
15 mg is tirzepatide's ceiling: 20.9% average loss at 72 weeks in SURMOUNT-1, the strongest studied result in the approved class — carrying the ladder's fullest side-effect load and the plateau question with nowhere higher to go. The top rung, examined.
Updated 2026-08-11
Semaglutide 0.25 mg: The Non-Therapeutic Starter — Four Weeks With One Job
0.25 mg is explicitly a tolerance dose — the label calls it non-therapeutic for glycemic control, and weight effects are incidental. What the first four weeks are for, why judging results here is a category error, and the intro-pricing economics that target exactly this phase.
Updated 2026-08-11
Semaglutide 0.5 mg: First Working Dose — Diabetes Maintenance, Weight-Loss Waypoint
0.5 mg wears two hats: a legitimate maintenance dose on the diabetes label (Ozempic) and the first real rung on the weight-loss climb to 2.4. What each pathway expects here, the modest-but-real effects, and the four-week evaluation.
Updated 2026-08-11
Semaglutide 1 mg: The Ozempic Workhorse and the Weight Ladder's Midpoint
1 mg is the diabetes label's classic maintenance dose — the SURPASS-2 comparator, the dose most 'Ozempic' prescriptions mean — and the weight ladder's halfway mark. What each identity expects, the head-to-head context, and the climb remaining.
Updated 2026-08-11
Semaglutide 1.7 mg: The Last Step Before Full Dose — the Weight Label's Staging Rung
1.7 mg exists on the weight-management ladder specifically — the four-week staging dose before 2.4, above the diabetes label's ceiling. What the penultimate step is for, the hold-here question, and the mechanics of the final climb.
Updated 2026-08-11
Semaglutide 2.4 mg: The Full Dose — the 14.9% Arm, the SELECT Dose, the Destination
2.4 mg is where semaglutide's evidence lives: 14.9% average loss at 68 weeks in STEP-1, the 20% cardiovascular risk reduction in SELECT, the head-to-head result against tirzepatide. The full-dose facts, maintenance at the top, and the 7.2 tier above it.
Updated 2026-08-11
How Much Does Tirzepatide Cost in 2026? Every Channel, One Answer
The complete tirzepatide price map: $25–$50 insured copays where covered, $125–$179 credible compounded, $299–$449 brand vials by dose with the 45-day rule, and the reseller tier above — with the routing logic that picks your channel in three questions.
Updated 2026-08-11
How Much Does Semaglutide Cost in 2026? Every Channel, One Answer
The complete semaglutide price map: $25 copays where covered, the $99–$139 compounded floor, the $149 approved oral tablet that squeezes it, $349 pens with a $199 introduction — and the routing that picks your lane in three questions.
Updated 2026-08-11
What the First 90 Days on a GLP-1 Actually Cost, Channel by Channel
Startup economics differ from steady state: brand titration rungs cost less, intro offers front-load savings, compounded flat rates don't move, and one-time costs cluster early. The honest 90-day budgets for every lane, and the traps in month four.
Updated 2026-08-11
The True 12-Month Cost of Every GLP-1 Path, Computed Honestly
Annual totals end arguments monthly prices start: $300 insured, $1,188–$2,148 compounded by commitment, ~$1,988 oral brand year one, $4,088–$5,388 injectable brand — with the assumptions stated and the failure modes (missed windows, unlocked promos) priced in.
Updated 2026-08-11
GLP-1s and Birth Control: The Tirzepatide Rule Every Label Reader Knows and Most Patients Don't
Tirzepatide's label carries a specific instruction: patients on oral contraceptives should use barrier backup for four weeks after starting and after each dose escalation — because delayed gastric emptying can reduce pill absorption exactly when exposure changes. The rule, the mechanism, and the semaglutide contrast.
Updated 2026-08-11
GLP-1s and Blood Pressure Medications: The Re-Dosing Cascade Nobody Schedules
Weight loss lowers blood pressure — which means yesterday's correct antihypertensive dose becomes tomorrow's excessive one, showing up as dizziness, fatigue, and falls that get blamed on the GLP-1. The monitoring rhythm, the symptoms that are actually numbers, and the deprescribing win hiding inside.
Updated 2026-08-11
Zepbound vs Wegovy: The Head-to-Head Trial, the Price Ladders, and the Honest Tiebreakers
The only direct comparison that exists — SURMOUNT-5's 20.2% vs 13.7% at 72 weeks — plus everything the single number leaves out: SELECT's cardiovascular indication, the sleep-apnea door, oral options, and cash ladders of $299–$449 versus $149–$399.
Updated 2026-08-11
Mounjaro vs Ozempic: The Diabetes Head-to-Head SURPASS-2 Already Ran
For type 2 diabetes the comparison has trial data: SURPASS-2 tested tirzepatide against semaglutide 1 mg head-to-head — tirzepatide won on A1c and weight at every dose. What the result means, its 1-mg asterisk, and how coverage actually decides this choice.
Updated 2026-08-11
Rybelsus vs Oral Wegovy: Two Semaglutide Tablets, Two Different Jobs
Both are oral semaglutide with the same brutal empty-stomach ritual — but Rybelsus carries the diabetes label at 7–14 mg while oral Wegovy carries the weight label at higher doses with ~15% trial results. The distinction, the OASIS data, and which tablet answers which question.
Updated 2026-08-11
Saxenda vs Wegovy: What the Older Daily Drug Still Answers in 2026
Liraglutide walked so semaglutide could run: daily injections, ~8% average loss in SCALE versus 14.9% in STEP — yet generics arriving since 2024, pediatric-label history, and formulary quirks keep Saxenda-class questions alive. The honest comparison and the niche that remains.
Updated 2026-08-11
Hims vs Ro in 2026: Two Post-Compounded Platforms, Two Different Bets
Both exited the compounded era into brand-only models — Hims as a membership storefront ($448–$548 all-in), Ro as an insurance concierge with a cash fallback ($448–$598). Same products, opposite theses; the comparison that routes by coverage status.
Updated 2026-08-11
Henry Meds vs bmiMD: The Flat-Rate Flagship Against the Ladder Champion
The two most-recommended budget programs solve the same problem differently: Henry's one-price-forever $179 simplicity versus bmiMD's four-rung ladder from $129/$179 down to $99/$139. The structural comparison, molecule by molecule, with the tie-breakers that actually decide.
Updated 2026-08-11
CagriSema: Novo's Next Act — the Amylin Combination and Its Roughly 23% Result
Semaglutide plus cagrilintide — an amylin analog — is Novo's answer to tirzepatide: REDEFINE-1 reported roughly 22.7% average loss at 68 weeks, short of the company's own 25% target but ahead of anything semaglutide achieves alone. What the combination is, the timeline, and the compounded warning that already applies.
Updated 2026-08-11
Orforglipron: The Small-Molecule GLP-1 Pill — No Needle, No Fasting Ritual, ~12% Results
Lilly's orforglipron is the class's manufacturing revolution: a non-peptide small molecule taken as a normal pill — no injection, none of oral semaglutide's empty-stomach ritual — with 2025 phase-3 readouts around 12.4% in obesity. Why 'good not spectacular' might still change everything.
Updated 2026-08-11
Survodutide: The Glucagon Dual Agonist Betting on the Liver
Boehringer's survodutide pairs GLP-1 with glucagon receptor agonism — phase-2 obesity results up to ~19%, and MASH data striking enough (improvement in up to ~83% of treated patients) to make the liver its headline. What the mechanism trades, and where the phase-3 program points.
Updated 2026-08-11
Generic Liraglutide: The Class's First Real Generic, and When It's Worth a Quote
Since 2024, generic liraglutide has given the GLP-1 class its first true generic lane — daily injections, ~8% SCALE-era results, prices that vary wildly by pharmacy. The honest guide to when the old drug's new price beats the new drugs' old prices.
Updated 2026-08-11
The GLP-1 Pipeline, August 2026: Every Drug Worth Watching, One Honest Page
The tracker: retatrutide's ~24% triple-agonist ceiling, CagriSema's ~23% and its expectations problem, orforglipron's ritual-free ~12% pill, survodutide's liver bet, amylin newcomers — with approval status, the no-legal-lane warning, and the only advice that survives every readout: treat now, switch later.
Updated 2026-08-11
Medicare and GLP-1s in 2026: The Exclusion, the Indication Doors, and the $50 Bridge
Part D still can't cover drugs 'for weight loss' by statute — but it covers the same drugs for diabetes, cardiovascular risk, and sleep apnea, and a July 2026 pathway reported a $50/month bridge. The map of what Medicare actually pays for, and how to file under the right door.
Updated 2026-08-11
Medicaid and GLP-1s: The State-by-State Reality, and How to Find Your Answer in One Call
Medicaid coverage for obesity medications is a state option — more than a dozen states have adopted it, most haven't, and diabetes-indication coverage runs everywhere. How to check your state in minutes, what the covering states require, and the paths when yours says no.
Updated 2026-08-11
The GLP-1 Prior Authorization, Done Right the First Time
Most PA denials are documentation failures, not coverage failures: missing BMI history, uncoded comorbidities, absent step-therapy records. The complete package that approves — what plans actually check, the timeline, and the prescriber-office choreography that makes it happen.
Updated 2026-08-11
Appealing a GLP-1 Denial: The Letter, the Levels, and Why Persistence Usually Wins
Denials are the system's first offer, not its final answer: internal appeals overturn a large share, external review exists by law when they don't, and the winning letter is documentation plus the plan's own criteria quoted back. The complete playbook, level by level.
Updated 2026-08-11
GLP-1s for Men: Testosterone, Muscle, and the Health Problems That Cluster
Men arrive with a specific cluster — visceral fat, sleep apnea, suppressed testosterone, cardiac risk — and major weight loss moves every item on it. What commonly improves and why, the muscle-preservation stakes, and the screening conversations worth having at intake.
Updated 2026-08-11
GLP-1s After 65: Sarcopenia Stakes, Slower Ramps, and the Polypharmacy Cascade
Older adults get real benefit from this class — and face its risks with less margin: muscle loss lands on age-depleted reserves, dehydration and dizziness carry fall stakes, and every weight-sensitive medication needs re-dosing. The geriatric-literate protocol.
Updated 2026-08-11
Hitting GLP-1 Protein Targets on a Vegetarian or Vegan Diet
1.2–1.6 g/kg of protein on a suppressed appetite is hard; doing it from plants adds a volume problem and a leucine question — both solvable with the right staples. The vegetarian playbook: the dense sources, the per-meal threshold, and the B12 note that's actually real here.
Updated 2026-08-11
Intermittent Fasting on a GLP-1: Usually Redundant, Sometimes Useful, Occasionally Risky
The drug already does what most people use fasting for — so stacking them is often under-fueling with extra steps. When IF still earns a place (structure, preference), the protein and hydration math it must survive, and the insulin/sulfonylurea case where it's genuinely unsafe without supervision.
Updated 2026-08-11
GLP-1s and Breastfeeding: What the Absence of Data Means in Practice
No adequate human data establishes safety of semaglutide or tirzepatide during lactation — which is why standard guidance runs conservative: these medications are generally deferred while breastfeeding, and compounded versions add unknowns on top of unknowns. The honest page, and the postpartum planning that actually helps.
Updated 2026-08-11
GLP-1 Constipation: The Fix Ladder That Works, and the Symptoms That Mean Call
Slowed motility plus smaller food volume makes constipation the class's most persistent complaint — and its most fixable, with a ladder that starts at fluids and fiber and ends at clinician-guided options. The protocol, the timeline, and the rare-but-real blockage signs.
Updated 2026-08-11
GLP-1 Nausea: Every Remedy That Actually Helps, Ranked by Evidence and Yield
Nausea is the class's signature side effect and its most manageable: meal mechanics do most of the work, a few home remedies genuinely help, prescription options exist for the hard cases, and the pattern itself — escalation echoes that fade — is half the reassurance. The complete toolkit.
Updated 2026-08-11
Injection Site Reactions: Normal, Annoying, or Infected — the Three-Bucket Guide
Most injection-site events are cosmetic and technique-responsive: small redness, bruises, itching, the occasional lump. The rotation and technique that prevent them, the buckets that classify them, and the spreading-redness-warmth-fever cluster that means call.
Updated 2026-08-11
Dehydration on GLP-1s: The Suppressed-Thirst Trap and the Electrolyte Protocol
Appetite suppression takes thirst down with it — quietly, which is why dehydration underlies half the class's 'side effects': headaches, fatigue, dizziness, constipation. The deliberate-intake protocol, when electrolytes matter, and the GI-illness escalation plan.
Updated 2026-08-11
The GLP-1 Telehealth Intake: What Happens, What to Answer Honestly, and the Red Flags
Between checkout and prescription sits the intake — an async questionnaire or video visit whose questions exist for your safety, not the program's paperwork. What legitimate intakes ask, why honesty on five items is non-negotiable, and the rubber-stamp signs that grade a program in one screen.
Updated 2026-08-11
Switching GLP-1 Providers Without a Gap, a Double-Dose, or a Billing Ghost
Provider-switching is routine — promo expirations, price drops, and service failures all justify it — and it has exactly three failure modes: a medication gap, an overlap double-dose, and the old subscription billing on. The clean-handoff protocol, step by step.
Updated 2026-08-11
How to Cancel a GLP-1 Subscription Cleanly: The Process, the Proof, and the Retention Gauntlet
Cancellation is a documentation exercise: find the actual mechanism, act before the renewal cutoff, capture written confirmation, and verify the next statement. The general protocol that works everywhere, plus the retention-offer math worth running before you say no.
Updated 2026-08-11
GLP-1 Refunds and Chargebacks: When to Dispute, How to Win, and What Not to Abuse
The credit card dispute is this market's last-resort protection — strongest for unauthorized and post-cancellation charges, real for paid-never-shipped, weak for buyer's remorse. The evidence pack, the sequence (merchant first), the timelines, and the honest limits.
Updated 2026-08-11
GLP-1 Scam Red Flags: The Eight Tells That End the Evaluation Immediately
Below the discount market sits the fraud market, and it telegraphs itself: no prescription required, crypto-only payment, prices under the floor of possibility, counterfeit brand pens, research-chemical fig leaves. The eight tells, why each one is disqualifying, and the two-minute legitimacy check.
Updated 2026-08-11
The GLP-1 Gray Market: What Buying From Peptide Sites and Forums Actually Risks
Research-chemical vials, group buys, and forum-sourced 'tirz' occupy the space below the legal market — and every step of that supply chain removes a protection: identity, purity, sterility, dosing infrastructure, legal standing, recourse. The clear-eyed risk map, and the legal lane that removes the motive.
Updated 2026-08-11
The GLP-1 Price Wars, 2021–2026: How $1,349 Became $99
Five years compressed the most expensive drug launch in memory into a functioning competitive market: launch lists near $1,350, the shortage-era compounding boom, LillyDirect's vial gambit and December 2025 restructuring, NovoCare's counterattack, the Hims settlement, and the compounded floor's slide to $99. The full history, with every date that still matters.
Updated 2026-08-11
The Cancellation Policy Census: Every Tracked Program's Exit Terms, Known and Unknown
The exit clause is the price nobody reads: this census records what our files establish about each tracked program's cancellation, refund, and pause terms — flat-rate simplicity, prepaid refund clauses, membership seams, promo-lock forfeitures — and marks 'unknown' honestly where captures don't reach, with the exact questions that fill each blank.
Updated 2026-08-11
The GLP-1 Market Report: August 2026 — Leaders, Deadlines, and What Breaks Next
The quarterly-style state of the market: computed category leaders and the margins behind them, the three dated windows closing this year, the regulatory docket that could reshape the compounded lane, verification-status distribution across all 37 tracked programs, and the watch-list for the next report.
Updated 2026-08-11
GLP-1 Side Effects A to Z: The Complete Tirzepatide and Semaglutide Reference
Every documented tirzepatide and semaglutide side effect in one alphabetical reference — from appetite changes to vomiting — with label frequencies, the boxed warning, the symptoms that mean stop-and-call, and links to the full guide on each.
Updated 2026-08-11
How to Verify a GLP-1 Compounding Pharmacy's License: The 15-Minute Masterclass
The complete verification workflow for any compounding pharmacy filling tirzepatide or semaglutide: getting the legal name, running the home-state license, checking the nonresident license in your state, confirming 503A/503B status on FDA's list, and reading the inspection record — with the red flags that end the check early.
Updated 2026-08-11
The GLP-1 Insurance Doors: Every FDA-Approved Indication That Opens Coverage in 2026
Coverage follows the diagnosis, not the molecule. The six doors — type 2 diabetes, weight management, cardiovascular risk, sleep apnea, chronic kidney disease, and MASH — which drug opens each, what the prior authorization asks for, and why the indication doors work even where weight-loss coverage doesn't.
Updated 2026-08-11
Medi-Cal and GLP-1s in 2026: What California Actually Cut on January 1, and Every Door Still Open
Effective January 1, 2026, Medi-Cal ended GLP-1 coverage for weight loss for adults 21 and older — Wegovy, Zepbound, and Saxenda came off the Contract Drug List for weight indications. What DHCS's own bulletins say still qualifies: diabetes, cardiovascular disease, kidney disease, the under-21 EPSDT path, appeals, and the cash reality.
Updated 2026-08-11
NC Medicaid and GLP-1s in 2026: The Coverage That Left and Came Back, Documented
North Carolina Medicaid covered GLP-1s for weight management from August 2024, paused it in 2025, then reinstated coverage effective December 12, 2025 under the Governor's directive — reverting to the September 30, 2025 criteria across Medicaid Direct and Managed Care. The bulletin record, the criteria, and the doors that never closed.
Updated 2026-08-11
The Medicaid GLP-1 Change Ledger: Every 2025–2026 State Move, Dated and Sourced
A running, dated record of state Medicaid GLP-1 weight-loss coverage changes: California's January 1 exit, North Carolina's December 12 reinstatement, the Utah pilot's June 30 end, Massachusetts's July 1 end, and the KFF count falling from sixteen to thirteen to roughly eleven — with each entry's evidentiary status labeled.
Updated 2026-08-11
The GLP-1 Price-Change Ledger: Every Dated Move in Our Database, 2026
A running, dated record of compounded and brand GLP-1 price movements: NexLife's Summer Sale rate card and Flat Forever lock, the semaglutide month-to-month floor passing from Oak Longevity to bmiMD, the ninety-nine-dollar twelve-month tier, NovoCare's introductory window, and the LillyDirect refill condition — every entry status-labeled, promotional rates never silently substituted.
Updated 2026-08-11
Michigan Medicaid and GLP-1s in 2026: The January 1 Restriction, the Morbid-Obesity Standard, and Every Door Still Open
Effective January 1, 2026, Michigan Medicaid restricted GLP-1 weight-loss coverage to the strictest standard of any covering state: morbid obesity, documented failure of other interventions, preferred-agent step therapy, and bariatric-surgery avoidance — per MDHHS notification L 25-73. What survived: diabetes coverage, the cardiovascular and sleep-apnea doors, and the under-21 path.
Updated 2026-08-11
Minnesota Medicaid and GLP-1s in 2026: Covered With Prior Authorization — and a Live Bill That Tried to End It
Minnesota's Medical Assistance program covers GLP-1s for weight loss with prior authorization and appears on every 2026 covering-state count — but a bill to prohibit that coverage reached committee in March 2026 before legislators delayed action. The record, the cost pressure behind the bill, and what to watch.
Updated 2026-08-11
Wisconsin Medicaid and GLP-1s in 2026: Tracker-Verified Coverage, ForwardHealth's Diagnosis-Restriction Mechanics, and One Conflict We Won't Paper Over
Wisconsin appears on every 2026 covering-state count for Medicaid GLP-1 weight-loss coverage, and ForwardHealth's own documents spell out the mechanics: preferred agents without PA but diagnosis-restricted on every prescription and claim, non-preferred agents under revised PA criteria with 183-day initial approvals. One directory claims no obesity benefit exists — here is the honest record.
Updated 2026-08-11
The Compounded GLP-1 Enforcement Record: Every FDA Wave, Dated — and What the Letters Actually Cite
From the 2025 warning-letter wave through the February 2026 enforcement announcement, the March 3 thirty-letter action, the April 30 proposal to strike semaglutide and tirzepatide from the 503B bulks list, and the June 8 wave that named companies for hiding their pharmacies — the dated record, the specific violations, and the buyer checklist that falls out of it.
Updated 2026-08-11
Virginia Medicaid and GLP-1s in 2026: Covered, Then Tightened — the BMI 40 Standard, the Form That Changed July 1, and the Renewal Math
Virginia Medicaid covers GLP-1s for weight loss with some of the country's strictest criteria — and tightened them mid-2026. The DMAS bulletin's BMI-40 (or 35-plus-two-conditions) standard, the service-authorization form's step therapy and five-percent renewal rule, age minimums by drug, and what existing authorizations keep.
Updated 2026-08-11
Delaware Medicaid and GLP-1s in 2026: The Quietly Stable Covering State
Delaware covers Wegovy, Zepbound, and Saxenda for weight loss with prior authorization — no restriction wave, no pending bill, no drama on the record. What that stability is worth, what the PA still requires, and what to verify anyway.
Updated 2026-08-11
Kansas Medicaid and GLP-1s in 2026: Restricted Coverage With Two Distinct Doors — Severe Obesity and the Wegovy Cardiovascular Pathway
KanCare covers Wegovy, Zepbound, and Saxenda under restricted prior-authorization criteria — a severe-obesity pathway plus a separate Wegovy cardiovascular pathway that is not the only route in. What the tracker verification establishes, what it doesn't, and the two-door strategy for Kansas enrollees.
Updated 2026-08-11
Mississippi Medicaid and GLP-1s in 2026: Covered With PA — and the Expansion Bill the Governor Vetoed Without Touching Existing Coverage
Mississippi covers Wegovy, Zepbound, and Saxenda for weight loss with prior authorization. In 2026 the legislature passed SB 2867 to expand the benefit; the governor vetoed it on fiscal grounds — and existing coverage continued unchanged. The record, the distinction that matters, and the standing doors.
Updated 2026-08-11
Missouri Medicaid and GLP-1s in 2026: The State That Moved Toward Coverage While Others Left
Missouri appears on every 2026 covering-state count, and the sourced state-by-state record marks it as an addition — a state that adopted GLP-1 weight-loss coverage while California, Pennsylvania, and others were cutting it. What's verified, what still needs the drug-list confirmation, and how to use it.
Updated 2026-08-11
Rhode Island Medicaid and GLP-1s in 2026: Covered With PA, on the Watch List
Rhode Island covers Wegovy, Zepbound, and Saxenda for weight loss with prior authorization — and has been publicly reported considering new restrictions since late 2025. The verified record, the watch status, and the renewal-timing strategy that status demands.
Updated 2026-08-11
Tennessee Medicaid and GLP-1s in 2026: Covered on Every Count — With the Drug List Still to Confirm
TennCare appears as a covering state on every 2026 count with prior authorization required — and the tracker record flags the specific drug list for verification. What's solid, what needs the one call, and the full door map for Tennessee enrollees.
Updated 2026-08-11
The CMS BALANCE Model, Explained: Negotiated GLP-1 Prices for Medicaid and Part D, the 2026 Application Window, and What Actually Changes for You
BALANCE is the federal government's attempt to make GLP-1 coverage affordable enough for states to keep: CMS-negotiated prices on Mounjaro, Ozempic, Wegovy, Zepbound, and the new oral orforglipron, a manufacturer-funded lifestyle program, standardized criteria, Medicaid applications through July 31, 2026, and coverage live by January 1, 2027. The honest assessment of what it will and won't fix.
Updated 2026-08-11
If the FDA Finalizes the 503B Exclusion: The Contingency Plan Every Compounded GLP-1 Subscriber Should Have Ready
The FDA's April 30, 2026 proposal would permanently remove semaglutide, tirzepatide, and liraglutide from the 503B bulks list — closing the pathway most subscription compounded programs run on. The comment period closed July 30; no decision has issued. The questions to ask your program now, the transition math, and exactly what this site updates the day a rule lands.
Updated 2026-08-11
The GLP-1 Glossary: Every Term That Gates Your Price, Coverage, or Safety, Defined Straight
Sixty-four working definitions — 503A vs 503B, BUD, COA, EPSDT, MACE, MASH, PA, PDL, rankable, salt forms, SELECT, SURMOUNT, titration, units-to-mg and the rest — each written to answer the question the term actually gates in the real market.
Updated 2026-08-11
The 45-Day Refill Window: The Most Expensive Calendar Rule in Pharma, and the Arithmetic of Missing It
LillyDirect's $299–$449 Zepbound vial pricing is conditional on refilling inside a 45-day window — miss it and the discounted self-pay structure resets. How the clock actually runs, what an off-window month costs against the $1,086-plus pen list price, the four ways people miss it by accident, and the calendar system that protects the discount.
Updated 2026-08-11
Flat vs Dose-Tiered Tirzepatide Pricing: The Math Over a Titration Year
Tirzepatide dosing is designed to escalate — which makes the pricing structure, flat or dose-tiered, worth more than the sticker. The titration schedule in months, why a cheaper tiered start loses to a flatter number by mid-year, the questions that expose a tier before you buy, and how our database records each structure.
Updated 2026-08-11
Vials, Units, and Reconstitution Math: The Arithmetic That Prevents the Most Common GLP-1 Injury
The FDA's adverse-event record for compounded GLP-1s traces overwhelmingly to at-home dosing errors — units read off the wrong concentration, reconstitution volumes guessed, milligrams and milliliters conflated. The three numbers on every vial, the one formula that converts between them, worked examples at real concentrations, and the checks that catch an error before it's injected.
Updated 2026-08-11
Start Price vs Maintenance Price: Anatomy of the Oldest Trick in GLP-1 Advertising
Every misleading GLP-1 ad runs the same play: quote the price of a month you'll leave against a competitor's price for the months you'll live in. The four variants of the trick — starter-dose pricing, first-month promos, microdose tiers, and funnel-gated maintenance — with a live example of each from our own database, and the two-question test that defeats all four.
Updated 2026-08-11
Membership Fees in GLP-1 Programs: The $75–$149 Shadow Price, and the All-In Accounting That Exposes It
A membership fee is a price that ships no medication — $75 to $149 a month across the programs that charge one, $900 to $1,600 a year of structural cost before a single vial. The live cases from our database (Zealthy's $135, Mochi's $79, LifeMD's fee-inside figure), the zero-fee programs that prove the fee is a choice, and the one-line question that surfaces every hidden membership.
Updated 2026-08-11
The True First-Year Cost of Tirzepatide, Month by Month
Not a sticker — a calendar. The twelve months of a standard tirzepatide first year priced at every decision point: titration months, the maintenance stretch, the promo reversion, the missed-window scenario, and the honest annual totals across compounded floors, market median, and the brand pathway.
Updated 2026-08-11
Tirzepatide 12-Month Prepaid Plans: The Discount vs the Concentration Risk
Prepaid plans buy a real discount with real risk: your money concentrates in one company, one pharmacy pathway, and one regulatory moment. The current prepaid ladder from the database, what the discount is actually pricing, the five questions that separate a good prepaid from a trap, and the 2026-specific reason to read refund terms before wiring a year.
Updated 2026-08-11
Why Compliant Compounded Tirzepatide Costs $249–$549 — and What a Price Below the Floor Is Telling You
The compounded tirzepatide market's compliant core runs roughly $249 to $549 all-in, with independent tracking putting the month-to-month average near $332. What that money buys — licensed compounding, testing, clinical oversight, cold-chain shipping — line by line, why the floor exists, and how to read a price far below it as the signal it is.
Updated 2026-08-11
Refund and Cancellation Terms Across GLP-1 Programs: A Comparative Reading of the Fine Print That Decides What Leaving Costs
Every program's price page shows what joining costs; the terms page shows what leaving costs, and the spread is wider. The structural patterns across our database's cancellation fields — notice periods, prepaid clawbacks, separately-billing memberships, quarterly cycles — what each pattern means in dollars, and the four screenshots to take on signup day.
Updated 2026-08-11